As expert consensus has been arisen about universal antiparasitic treatment for all patients infected with Trypanosoma cruzi, most important drugs licensed for Chagas disease treatment are reviewed: nifurtimox and benznidazol, their mechanisms of action, doses, treatment schedules, adverse effects and contraindications. Two other drugs used for Chagas disease treatment, for which a Chilean experience may be exhibited, are allopurinol and itraconazole. Indications for treatment of Chagas disease in immunocompetent patients and inmunocompromised hosts are detailed. This chapter refers besides to the evaluation and monitoring of antiparasitic therapy in inmunocompromised patients, the availability of drugs and includes various forms facsímiles suggested to perform clinical and laboratory follow up of patients that undergo treatment, indicating the prescribed drug, adverse effects and time of follow up. © 2008 Sociedad Chilena de Infectología.
CITATION STYLE
Apt B., W., Heitmann G., I., Jercic L., M. I., Jofré M., L., Muñoz C. Del V., P., Noemí H., I., … Zulantay A., I. (2008, October). Guías clínicas de la enfermedad de Chagas 2006: Parte VI. Tratamiento antiparasitario de la enfermedad de Chagas. Revista Chilena de Infectologia. https://doi.org/10.4067/s0716-10182008000500013
Mendeley helps you to discover research relevant for your work.